Rheumatology Billing Services
Rheumatology is the specialty where the practice buys its own inventory. Under buy-and-bill you have already paid for the biologic before the claim goes out, so a documentation gap does not shave a fee — it turns an acquisition cost into a write-off. That is the exposure we are hired to manage, and it is a billing-process problem rather than a clinical one. We run the infusion claim end to end. Before the chair time is booked we confirm the authorization is in hand and still valid on the date of service, that the conventional-DMARD trial the plan requires is documented with dates and a recorded response, and that the plan's biosimilar rule has been checked against what was actually ordered — because a reference-product order placed against a biosimilar mandate becomes a denial after the drug has been bought. On the claim itself we convert the administered dose into the billing units that specific HCPCS code is defined in, which is not the vial and not always the milligram. We report the discarded amount on its own line with the waste modifier, and the attestation modifier where nothing was discarded, with container size and discarded quantity in the record behind both. We code the administration separately from the drug and time it off the documented start and stop times, because a claim that carries the drug and forgets the administration gives up the whole chair-time component. We code joint injections by joint size and by whether guidance with permanent recording was used, with the medication billed on its own line. Then we work the result rather than letting it age: denials, underpayments, and the Part B drug payment limit, which is republished quarterly and is re-checked against your remittances instead of assumed. We work with rheumatology practices running in-office biologic infusion programs where drug cost is at risk before payment, and with practices whose A/R is concentrated in drug-code and prior-authorization denials.
- Free audit
- No contract
- HIPAA-secure
- Cancel anytime
What do rheumatology billing services cover?
We bill rheumatology practices from the infusion chair through final A/R, and the money in this specialty sits in the buy-and-bill program, where you have paid for the drug before the claim goes out. We file the drug line with the administered dose converted into that code's own billing units, the discarded amount on a separate line with the waste modifier, the attestation modifier on single-dose-container claims where nothing was discarded, and the administration tiers timed off documented start and stop times. We check the biosimilar formulary and the conventional-DMARD trial documentation before the infusion is booked, not after the denial. And we re-check the Medicare Part B drug payment limit against your remittances every quarter, because it is republished on that cycle — what you paid the distributor is not what the claim is priced against, and drug margin moves underneath you if nobody is watching it.
- Buy-and-bill J-code billing for in-office biologics with the administered dose converted into that code's own billing units - 10 mg for infliximab (J1745), 1 mg for tocilizumab (J3262)
- JW filed on the documented single-dose-container residual, and JZ filed to attest zero waste - Medicare has required JZ since 1 July 2023
- Step-therapy packets carrying the conventional-DMARD trial dates, doses and documented response before the biologic authorization goes in
- Biosimilars billed on their own HCPCS codes, not on the reference product's - Q5103, Q5104 and Q5121 are separate codes from J1745
- Joint injections coded by joint size and by whether ultrasound guidance was used, since guidance is built into 20604/20606/20611 rather than billed separately
Who This Page Is For
Common Billing Friction in Rheumatology
Buy-and-bill infusions - the JW and JZ modifiers and the dose-to-units conversion
Biologic infusion drugs come in single-dose containers sized for typical adult dosing, and weight-based dosing rarely lands on a clean vial multiple, so some of the drug is discarded. Medicare pays for the discarded amount as well as the administered dose, up to the amount on the container labeling, when the discarded units are reported on a separate claim line with the JW modifier - and since 1 July 2023 it requires the JZ modifier on single-dose-container claims where nothing was discarded, as an attestation. The policy applies in general to drugs separately payable under Part B that FDA-approved labeling describes as supplied in a single-dose container or single-use package; vaccines furnished from single-dose containers are excluded. Two failure modes do the damage. The first is an unmodified claim line, which is a compliance exposure now that JZ is mandatory rather than merely a lost waste payment. The second is a units error: billing units are defined per HCPCS code, not per vial and not per milligram, so a dose has to be converted deliberately every time. Each biologic bills on its own J-code with its own unit definition and its own vial sizes — J1745 infliximab (Remicade), J0129 abatacept (Orencia), J9312 rituximab (Rituxan) and J3262 tocilizumab (Actemra) — so the conversion has to be redone per drug rather than carried across from the last one - and the record has to show the container size and the discarded amount to survive review. We do not publish an annual waste-revenue figure, because it is a function of your own dose distribution against your own vial sizes and is measurable from your claims rather than assertable in advance. Source: CMS, Discarded Drugs, verified 17 September 2026.
Step therapy gates - conventional DMARD failure before biologic approval
Commercial payers generally require documented failure of or intolerance to a conventional DMARD - methotrexate is the usual first step, with sulfasalazine, leflunomide and hydroxychloroquine layered in depending on the diagnosis - before approving a biologic for rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. Failure means a documented inadequate response after an adequate trial at an adequate dose, supported by disease activity measurement, or a documented adverse reaction. Authorization packets without that trial documentation get denied at first review. Two qualifications matter and are routinely dropped: the requirement is set plan by plan and product by product, not nationally, so a Medicare Advantage product and a commercial product from the same carrier can differ; and lupus, vasculitis and the other autoimmune indications have their own step structures rather than sharing the rheumatoid arthritis one. The practical rule is to pull the specific plan's policy for the specific diagnosis before the packet is built.
Biosimilar mandates - and the fact that a biosimilar is a different HCPCS code
A number of commercial plans require a biosimilar before covering the reference biologic, with brand-name coverage available only on a documented biosimilar failure or a specific medical exception. The formulary side of this is well understood; the claims side is where practices lose money. A biosimilar is not billed on the reference product's code. The Medicare descriptor for J1745 is explicit that it is infliximab excluding biosimilar, and the infliximab biosimilars carry their own codes - Q5103 for infliximab-dyyb (Inflectra), Q5104 for infliximab-abda (Renflexis) and Q5121 for infliximab-axxq (Avsola). Each has its own payment limit in the quarterly ASP file. So a practice that switches product to satisfy a mandate but keeps billing the old code is generating a mismatch between what was acquired, what was administered and what was claimed - the exact chain that a drug-utilization audit follows. Codes and descriptors from the CMS HCPCS file, read 17 September 2026.
Infusion time-tier coding - 96365, 96366, 96367, 96368 and the start/stop documentation
IV infusion administration codes in tiers, and on the CY2026 Medicare national non-facility amounts they are worth roughly: 96365 first hour of a single drug about $67, +96366 each additional hour about $21, 96367 sequential infusion of a different drug about $30, 96368 concurrent infusion about $21. A three-hour infusion of a biologic preceded by a separate pre-medication infusion codes as 96365 plus two units of 96366 for the biologic, plus 96367 for the sequential pre-medication - about $139 in administration on those figures, which is why a claim carrying only the J-code leaves real money behind. Documentation has to include start and stop times for each drug; without them the tier structure cannot be defended and the add-on units are the first thing a reviewer removes.
Joint injection by joint size - and the guidance codes that replace, rather than add to, 20600/20605/20610
Arthrocentesis and injection codes split by joint size, and again by whether ultrasound guidance with permanent recording was used. On the CY2026 Medicare national non-facility amounts: without ultrasound guidance, 20600 small joint about $56, 20605 intermediate about $57, 20610 major joint about $69; with ultrasound guidance, 20604 about $87, 20606 about $94, 20611 about $104. This is the correction worth making, because the opposite is widely published: CMS describes 20600-20611 as one family covering arthrocentesis of different sized joints or bursae with or without ultrasound guidance, so the guided study is billed by choosing the guided code, not by adding 76942 to the unguided one. CMS also states the unit of service is the joint and its surrounding bursae, so aspirating a shoulder and two of its bursae is still one unit of 20610. The medication is billed separately on its own J-code: J3301 for triamcinolone acetonide in 10 mg units, and for hyaluronic acid the units differ by product - J7321 (Hyalgan, Supartz, Visco-3) bills per dose while J7325 (Synvisc, Synvisc-One) bills per milligram, so one single-injection administration of a J7325 product is reported as its full milligram dose in units, not as one unit. Bilateral injections take modifier 50 or RT/LT depending on the plan. Source: CMS NCCI Policy Manual Chapter IV and the CY2026 HCPCS and PFS files, read 17 September 2026.
Rheumatology-Specific Payer Issues We Watch For
UnitedHealthcare
Issue: UnitedHealthcare generally requires step-therapy documentation showing failure of at least one conventional DMARD before authorizing biologic therapy, and applies biosimilar-first policies on some plans but not others - the requirement is set by plan and product rather than across the carrier
Our approach: We compile step therapy failure documentation including drug name, dosage, duration, and clinical response before submitting biologic prior authorization, and verify biosimilar-first requirements per plan
Aetna
Issue: Aetna mandates biosimilar substitution for certain reference biologics on certain plans and denies the reference product without a medical exception documenting biosimilar failure. Because the biosimilar is a different HCPCS code, a product switch that is not carried through to the claim produces a second denial after the first one is resolved
Our approach: We check the plan's biosimilar requirement before each infusion is booked, submit medical-exception requests with clinical documentation where the reference product is necessary, and change the billing code when the product changes
Medicare
Issue: Medicare requires a waste modifier on claims for drugs supplied in single-dose containers: JW on a separate line for a documented discarded amount, and since 1 July 2023 JZ to attest that nothing was discarded. The record has to show the container size and the discarded amount, and vaccines furnished from single-dose containers are excluded from the policy
Our approach: We build the container size and discarded amount into the infusion record at the chair, then file JW with the discarded units on its own line or JZ where there is none, so neither the waste payment nor the attestation is missing
Cigna
Issue: Applies specialty pharmacy mandates that redirect buy-and-bill infusions to home infusion, reducing practice revenue and clinical oversight of biologic administration
Our approach: We document clinical necessity for office-based infusion (monitoring requirements, anaphylaxis risk) and submit medical exception requests to maintain in-office administration
What We Handle
Biologic infusion buy-and-bill - dose, units, waste and administration
J-code billing for the major infused biologics with the administered dose converted into that code's own billing units, JW on the documented single-dose-container residual and JZ where nothing was discarded, and the time-tier administration codes (96365, 96366, 96367, 96368) filed alongside the drug line rather than instead of it.
Step therapy, biosimilar formulary and prior authorization packets
Step-therapy documentation packets carrying the conventional-DMARD trial dates, doses and inadequate-response or intolerance evidence; biosimilar checks against the specific plan and product before the order is placed, including the code change that follows a product switch; and medical-exception submissions with supporting documentation where the reference product is clinically necessary.
Joint injections - 20600-20611 with J-code pairing
Joint-size-specific arthrocentesis coding that selects the guided code (20604, 20606, 20611) where ultrasound guidance with permanent recording was used and the unguided code (20600, 20605, 20610) where it was not, paired with the drug J-code in that code's own units, modifier 50 or RT/LT for bilateral, and same-day E/M coordination with modifier 25 where a separately identifiable evaluation supports billing both.
E/M coding for multi-system autoimmune disease
MDM-driven E/M coding (99214, 99215) for lupus with multi-organ involvement, RA with biologic management, vasculitis, scleroderma, and the high-complexity decision-making that justifies higher-tier visit codes when documentation supports it.
Lab and disease-activity monitoring billing
Billing for ANA (86038), rheumatoid factor (86430), anti-CCP (86200) and inflammatory markers (ESR 85652, CRP 86140), which are clinical laboratory fee schedule services rather than physician fee schedule ones, plus therapeutic drug assays where a specific analyte code exists and the unlisted quantitative assay (80299) where it does not. Disease-activity composite scores such as DAS28 and CDAI are documentation that supports the E/M level and the biologic authorization; they are not themselves separately billable services.
Image-guided injection coding done the right way round
Guidance is coded into the procedure, not bolted onto it. For joint and bursa injections that means choosing 20604, 20606 or 20611 when ultrasound guidance with permanent recording and reporting was performed, rather than adding 76942 to an unguided code. Where a separate guidance code genuinely applies - a soft-tissue or tendon-sheath procedure outside the 20600-20611 family, or fluoroscopic guidance on a procedure whose descriptor does not include it - we bill it with the saved images and the medical-necessity language that supports it.
Free Billing Audit · No obligation
Is your rheumatology billing leaving money on the table?
We audit your last 90 days of rheumatology claims for under-coding, modifier errors, and denials — and show you the recoverable dollars at no cost. Written findings in 3–5 business days.
Prefer to talk? Book a 15-minute callRequest received
A billing specialist will review your practice details and reach out within 1 business day. No confirmation email is sent — if you need to reach us sooner, call +1-872-297-2815.
Key Rheumatology CPT Codes
| CPT Code | Description | Medicare Amount CY2026 national, non-facility |
|---|---|---|
| 96365 | IV infusion, therapeutic, initial, up to 1 hour | $67 |
| 96366 | IV infusion, therapeutic, each additional hour | $21 |
| J1745 | Infliximab, excludes biosimilar, per 10 mg (biosimilars bill on Q5103, Q5104 or Q5121) | — |
| J3262 | Tocilizumab (Actemra), per 1 mg | — |
| 20610 | Arthrocentesis, major joint, without ultrasound guidance | $69 |
| 20600 | Arthrocentesis, small joint, without ultrasound guidance | $56 |
| 99215 | Office visit, established patient, high complexity | $192 |
| 86200 | Cyclic citrullinated peptide antibody (anti-CCP) - clinical lab fee schedule, not the PFS | — |
Amounts are the Medicare national unadjusted non-facility amounts for CY2026, computed from the published CMS relative value file. They are not what a commercial payer pays, and your locality adjustment moves them. A dash means Medicare publishes no amount for that code — because it is non-covered, bundled, or priced outside the fee schedule.
Why General Billing Teams Miss Rheumatology Issues
General billing staff handle dozens of specialties and rarely develop the depth needed for rheumatology coding nuances. Here is what gets missed.
Modifier and bundling errors
Specialty-specific modifier rules and CCI edits are frequently overlooked by teams that do not work exclusively in rheumatology.
Under-coding high-complexity visits
Rheumatology encounters often qualify for higher-level E/M codes, but generalist billers default to mid-level codes to avoid audit risk.
Missed payer-specific rules
Each payer has unique coverage and documentation requirements for rheumatology procedures that general teams rarely memorize.
Slow denial turnaround
Without specialty knowledge, appeal letters lack the clinical specificity needed to overturn rheumatology denials quickly.
“In this specialty the drug is already paid for by the time the claim goes out, so the failure is never a small one. Every infusion should reconcile four ways before it is filed: authorization valid that day, dose converted into the code's own units, waste modifier present, and payment checked against the current quarter's ASP limit rather than against what the practice paid.”
MedPrecision Billing Team
Rheumatology Billing and Infusion Therapy Specialist
Transition Plan
Switching billing partners should not disrupt patient care or cash flow. Our transition plan is designed for zero downtime.
Discovery and Specialty Audit
We review your current rheumatology billing workflows, denial patterns, and payer mix to build a tailored onboarding plan.
System Integration
We connect to your EHR and practice management system, configure specialty-specific code sets, and validate charge capture workflows.
Parallel Billing Period
We run billing in parallel with your current process for 2-4 weeks to verify accuracy before taking over completely.
Full Transition and Reporting
Once validated, we assume full billing responsibility with monthly reporting dashboards and a dedicated account manager.
Rheumatology Billing Terms
- Buy-and-Bill (Rheumatology)
- A model where the practice purchases the biologic, administers it in-office, and bills the payer for both the drug (its HCPCS code, in that code's own billing units) and the infusion administration (96365-96368). Because the drug is bought before the claim is paid, inventory, dose-to-units conversion and waste documentation are financial controls rather than clerical ones.
- Drug Waste (JW and JZ Modifiers)
- JW reports the discarded amount from a single-dose container on its own claim line so Medicare pays for it alongside the administered dose; JZ attests that nothing was discarded and has been required on single-dose-container claims since 1 July 2023. The record must show the container size and the discarded amount. Vaccines furnished from single-dose containers are excluded.
- Biosimilar Mandates
- Payer policies requiring a biosimilar before the reference biologic is covered. Common for infliximab and adalimumab. The point that affects the claim rather than the formulary: a biosimilar has its own HCPCS code - the infliximab biosimilars are Q5103, Q5104 and Q5121, while J1745 is defined as infliximab excluding biosimilar - so a product switch has to change the billed code.
- Step Therapy
- A payer requirement that patients try and fail less expensive therapies before more expensive treatments are authorized. In rheumatology, typically requires documented failure of conventional DMARDs before biologic approval.
- Joint Injection Coding by Size and Guidance
- 20600-20611 is a single family covering arthrocentesis and injection of different sized joints or bursae with or without ultrasound guidance: 20600/20604 small joint, 20605/20606 intermediate, 20610/20611 major joint, with the second code in each pair used when ultrasound guidance with permanent recording was performed. The unit of service is the joint and its surrounding bursae.
- DMARD (Disease-Modifying Antirheumatic Drug)
- Medications that slow or stop the progression of autoimmune diseases. Conventional DMARDs (methotrexate, sulfasalazine) are first-line treatments, while biologic DMARDs (Remicade, Enbrel, Humira) are used when conventional therapy fails.
Last updated: 2026-09-17
Common Questions
Common questions about rheumatology billing services.
Request a Specialty Billing Review
See how specialty-specific billing support can improve reimbursement visibility for rheumatology billing services.
Request ReviewHow do you protect the margin on biologic infusions?
By making the four steps reconcile: authorization valid on the date of service, administered dose converted into the HCPCS code's own billing units, the correct waste modifier on the claim, and the payment checked against the current Part B limit rather than against acquisition cost. Medicare pays for a documented discarded amount from a single-dose container when the JW modifier is on a separate line, and since 1 July 2023 it requires the JZ modifier to attest that nothing was discarded - CMS, Discarded Drugs, verified 17 September 2026. The payment limit for most separately payable Part B drugs is the average sales price plus 6 percent, and because that file is republished quarterly we re-check drug margin each quarter instead of treating it as fixed.
How do you handle prior authorization for biologics?
We compile the conventional-DMARD trial documentation, the disease activity measurements and the clinical notes supporting necessity, check the specific plan and product for a biosimilar requirement before the order is placed, and submit well ahead of the scheduled infusion so a denial can be appealed - with peer-to-peer support where the plan offers one - before the chair time is lost. Where a mandate forces a product switch we change the billing code with it, because a biosimilar has its own HCPCS code rather than sharing the reference product's.
Can you bill for joint injections and an office visit on the same day?
Yes. When the office visit involves a separately identifiable evaluation beyond the injection decision, we bill both the E/M code with modifier 25 and the injection procedure code. Documentation must support the medical necessity of both the visit and the injection as separate services.
Related Services
Related Specialties
Related Resources
Request a Specialty Billing Review
See whether your infusion claims reconcile - authorization, administered dose, billing units, waste modifier and the payment you actually received.
- No contract
- No setup fees
- Reply within 1 business day